(PDF) P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent

P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.562

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

INTERNATIONAL PERSPECTIVE: Management of Chemotherapy-Induced Febrile Neutropenia Among Adult Oncology Patients: A Review

Canadian Oncology Nursing Journal

English

P1.01-90 a Pilot Trial Assessing Apatinib Combined With Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn345 - Health State Utilities in Metastatic Nsclc: A Study of Multiple Immuno-Oncology Trials

Value in Health

Occupational Health

English

P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab

Journal of Thoracic Oncology

Respiratory Medicine

English

Incidence of Chemotherapy-Induced Neutropenia in HIV-infected and Uninfected Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

South African Medical Journal

English

P1.01-34 Docetaxel Plus Ramucirumab With Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Predictive Models for Chemotherapy-Induced Febrile Neutropenia in Breast Cancer Patients: A Validation Study

Multidisciplinary

English

Micafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients With Febrile Neutropenia

Internal Medicine

Internal Medicine

English

Immuno‐Oncology Forum

Asia-Pacific Journal of Clinical Oncology

English